Tags

Type your tag names separated by a space and hit enter

A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Eur J Gastroenterol Hepatol. 2013 May; 25(5):601-5.EJ

Abstract

BACKGROUND AND OBJECTIVE

Nowadays, interferon alfa-2b is still in widespread use for the treatment of chronic hepatitis C in China. In this study, peginterferon alfa-2a plus ribavirin was compared with interferon alfa-2b plus ribavirin for the initial treatment of genotype 1 chronic hepatitis C.

MATERIALS AND METHODS

Overall, 168 patients with genotype 1 chronic hepatitis C were assigned peginterferon alfa-2a (135-180 µg subcutaneously/week) plus ribavirin (800-1200 mg/day orally) or interferon alfa-2b (300-500 million units, once every other day) plus ribavirin (800-1200 mg/day). According to HCV RNA levels at weeks 4 and 12, patients were reallocated to receive different interferon dosage forms or different courses of treatment. The primary endpoint was a sustained virological response (SVR).

RESULTS

A total of 160 patients completed the entire study and eight cases were lost to follow-up. The SVR rates in patients treated with peginterferon alfa-2a plus ribavirin for 24 and 48 weeks were 67.9% (53/78) and 73.6% (14/19), respectively, whereas in patients treated with interferon alfa-2b plus ribavirin for 24 and 48 weeks the SVR rates were 52.4% (43/82) and 40% (8/20), respectively. The SVR rates in the groups with a rapid virological response (RVR) and without RVR were 68.8 and 16.9%, respectively. The SVR rates in the groups with an early virological response (EVR) and in the groups without EVR were 88.1 and 10.5%, respectively.

CONCLUSION

Peginterferon alfa-2a plus ribavirin was more effective than interferon alfa-2b plus ribavirin, with similar safety. RVR can predict a greater chance of SVR. The duration of treatment should be shortened for patients with RVR. Treatment for patients without EVR should be discontinued.

Authors+Show Affiliations

Tianjin Infectious Disease Hospital, Tianjin, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

23263720

Citation

Ma, Ping, et al. "A Preliminary Study On the Efficacy and Influencing Factors of Interferon for the Treatment of Genotype 1 Chronic Hepatitis C With Different Dosage Forms." European Journal of Gastroenterology & Hepatology, vol. 25, no. 5, 2013, pp. 601-5.
Ma P, Yang JM, Hou W, et al. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. Eur J Gastroenterol Hepatol. 2013;25(5):601-5.
Ma, P., Yang, J. M., Hou, W., Song, S. D., Wang, L., & Lu, W. (2013). A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. European Journal of Gastroenterology & Hepatology, 25(5), 601-5. https://doi.org/10.1097/MEG.0b013e32835cc899
Ma P, et al. A Preliminary Study On the Efficacy and Influencing Factors of Interferon for the Treatment of Genotype 1 Chronic Hepatitis C With Different Dosage Forms. Eur J Gastroenterol Hepatol. 2013;25(5):601-5. PubMed PMID: 23263720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. AU - Ma,Ping, AU - Yang,Ji-Ming, AU - Hou,Wei, AU - Song,Shi-Duo, AU - Wang,Lei, AU - Lu,Wei, PY - 2012/12/25/entrez PY - 2012/12/25/pubmed PY - 2013/9/26/medline SP - 601 EP - 5 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 25 IS - 5 N2 - BACKGROUND AND OBJECTIVE: Nowadays, interferon alfa-2b is still in widespread use for the treatment of chronic hepatitis C in China. In this study, peginterferon alfa-2a plus ribavirin was compared with interferon alfa-2b plus ribavirin for the initial treatment of genotype 1 chronic hepatitis C. MATERIALS AND METHODS: Overall, 168 patients with genotype 1 chronic hepatitis C were assigned peginterferon alfa-2a (135-180 µg subcutaneously/week) plus ribavirin (800-1200 mg/day orally) or interferon alfa-2b (300-500 million units, once every other day) plus ribavirin (800-1200 mg/day). According to HCV RNA levels at weeks 4 and 12, patients were reallocated to receive different interferon dosage forms or different courses of treatment. The primary endpoint was a sustained virological response (SVR). RESULTS: A total of 160 patients completed the entire study and eight cases were lost to follow-up. The SVR rates in patients treated with peginterferon alfa-2a plus ribavirin for 24 and 48 weeks were 67.9% (53/78) and 73.6% (14/19), respectively, whereas in patients treated with interferon alfa-2b plus ribavirin for 24 and 48 weeks the SVR rates were 52.4% (43/82) and 40% (8/20), respectively. The SVR rates in the groups with a rapid virological response (RVR) and without RVR were 68.8 and 16.9%, respectively. The SVR rates in the groups with an early virological response (EVR) and in the groups without EVR were 88.1 and 10.5%, respectively. CONCLUSION: Peginterferon alfa-2a plus ribavirin was more effective than interferon alfa-2b plus ribavirin, with similar safety. RVR can predict a greater chance of SVR. The duration of treatment should be shortened for patients with RVR. Treatment for patients without EVR should be discontinued. SN - 1473-5687 UR - https://www.unboundmedicine.com/medline/citation/23263720/A_preliminary_study_on_the_efficacy_and_influencing_factors_of_interferon_for_the_treatment_of_genotype_1_chronic_hepatitis_C_with_different_dosage_forms_ L2 - http://dx.doi.org/10.1097/MEG.0b013e32835cc899 DB - PRIME DP - Unbound Medicine ER -